- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02903355
Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hearing loss can render a soldier less able to detect and identify the enemy, less able to understand commands, particularly in background noise typical on the battlefield, and may permanently reduce quality of life. In some cases, hearing loss may preclude redeployment or result in less optimal job assignment. Currently, no FDA approved pharmacological prevention exists for noise-induced hearing loss (NIHL). We have documented in animal studies that administration of D-methionine (D-met) can reduce or prevent NIHL. We now need to determine if it has similar efficacy in humans. Although we have not yet tested D-met on protection from noise-induced tinnitus in animals, this clinical trial would provide us the opportunity to also test for protection from noise induced tinnitus simultaneously.
Objective Hypotheses:
Primary Hypothesis: Administration of oral D-methionine prior to, during and 4 days post-weapons training will reduce or prevent permanent noise-induced hearing loss.
Secondary Hypothesis: Administration of oral D-methionine prior to, during and 4 days post-weapons training will reduce or prevent noise-induced tinnitus.
Specific Aims:
To determine whether administering oral D-met can prevent permanent NIHL after weapons training. This aim will be addressed by comparing the results of D-met versus placebo administration starting 3 days prior to, during the 11 day period of weapons training (Monday-Friday for first week, Monday-Thursday for second week), and 4 days after for a total of 18 days. Pure tone hearing thresholds will be assessed before and 22 days after completion of weapons training (ie; 18 days after the last day of study drug/placebo administration).
To determine whether administering oral D-met can prevent tinnitus after weapons training. This aim will be addressed by comparing the results of D-met versus placebo administration starting 3 days prior to, during the 11 day period of weapons training (Monday-Friday for first week, Monday-Thursday for second week), and 4 days after for a total of 18 days. Tinnitus questionnaires will be assessed before and 22 days after completion of weapons training (ie; 18 days after the last day of study drug/placebo administration).
To monitor for any potential side effects of D-met in human subjects. This aim will be accomplished by subject query on each day study drug is dispensed (twice daily) and at final study visit, routing of any adverse event reports to study medical personnel, statisticians and to the Food and Drug Administration (FDA).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
South Carolina
-
Fort Jackson, South Carolina, United States, 29207
- Moncrief Army Community Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Male or female 21 to 45 years of age Negative pregnancy test at enrollment and prior to taking study drug Willing to use an effective method of birth control during the study (Both male and female participants should avoid pregnancy during study) Pure tone air conduction threshold average at 0.5, 1 and 2 kHz of no greater than 40 dB HL bilaterally with no air bone gaps greater than 10 dB and normal otoscopy and tympanometry screens Willing to refrain from using supplements containing or derived from protein while participating in this study Ability to comply with all study requirements
Exclusion criteria:
History of allergic or idiosyncratic reaction to methionine, amino acid mixtures, nutritional supplements, egg white, or other proteins or food additives Vegetarian (Individual excludes meat and fish from their diet) History of chronic balance disorders Abnormal otoscopic findings, otologic surgery, autoimmune inner ear disease, significant air-bone gaps, abnormal tympanograms or other indication of middle-ear abnormality, history of fluctuant hearing or asymmetric hearing worse than 25 dB at any frequency in either ear, perilymphatic fistula, tumor of the auditory system, or other CNS disorder that is likely to affect hearing Treatment with intravenous (IV) antibiotics within the past 6 months Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug Treatment for alcohol or substance abuse within past 6 months Women of childbearing age who are not using effective contraceptive methods and who may become pregnant during the course of the study Women who are pregnant or breastfeeding. National Guardsmen History of psychotic schizophrenia Exposure within the previous 6 months to systemic ototoxic substances including aminoglycosides or vancomycin Body weight exceeding 225 pounds Renal impairment measured as eGFR < 50 on screening creatinine clearance blood draw.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
|
Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
|
Experimental: D-methionine, oral liquid suspension
D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
|
D-methionine, oral liquid suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ASHA Shift Ear (Left)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
ASHA Shift Ear (Right)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
ASHA Shift Ear (Either)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
ASHA Shift Ear (Both)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
ASHA Shift Ear (Trigger Hand)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
ASHA Shift Ear (Non-Trigger Hand)
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 20 dB at any one frequency, An increase of at least 10 dB at any two consecutive frequencies, or Loss of response at 3 consecutive frequencies where responses were obtained at baseline. |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DOEHRSHC Shift
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Greater than or equal to 10 dB change for the average of 2k, 3k, and 4k in either ear.
This is a binary outcome measure based on meeting this definition.
|
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
EWS STS Shift
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Greater than or equal to 15 dB change (deficit) in any of the following frequencies in either ear (1k or 2k or 3k or 4k).
This is a binary outcome measure based on meeting this definition.
|
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Total THI Score Change
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Tinnitus Handicap Inventory.
Tinnitus handicap inventory designed to evaluate the difficulties experienced as a result of hearing loss.
Score ranges from 0 to 100 with 0 indicating no handicap, and 100 indicating catastrophic handicap.
The THI score was to compare pre and post treatment effects of hearing loss.
|
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Significant Change in Tinnitus
Time Frame: Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
An increase of at least 5 points in the Tinnitus Handicap Inventory (THI), AND an increase in one severity grade category (Categories listed below). Tinnitus handicap inventory is designed to evaluate the difficulties experienced as a result of hearing loss. Score ranges from 0 to 100, with 0 indicating no handicap, and 100 indicating catastrophic handicap. The THI score was to compare pre and post treatment effects of hearing loss. 0-16: Slight or no handicap (Grade 1) 18-36: Mild handicap (Grade 2) 38-56: Moderate handicap (Grade 3) 58-76: Severe handicap (Grade 4) 78-100: Catastrophic handicap (Grade 5) |
Change from baseline to day 29-36 after initial administration of study drug (Day 15-22 after cessation of weapons training).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kathleen Campbell, PhD, MetArmor, Inc.
- Study Director: CPT William Grimes, MD, United States Department of Defense, US Army Ft. Jackson, South Carolina
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01345474
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Noise-induced Hearing Loss
-
University Hospital, AntwerpUnknownNoise-induced Hearing Loss | Noise-induced TinnitusBelgium
-
University of MichiganNational Institute on Deafness and Other Communication Disorders (NIDCD); Progressive...CompletedNoise-induced Hearing LossUnited States
-
University of MichiganUniversity of Florida; National Institute on Deafness and Other Communication... and other collaboratorsCompleted
-
Otologic Pharmaceutics, Inc.CompletedHearing Loss | Sensorineural Hearing Loss | Noise-Induced Hearing LossUnited States
-
Edison Pharmaceuticals IncCompletedNoise-induced Hearing LossUnited States
-
Washington University School of MedicineWithdrawn
-
Marjorie McCullaghNational Institutes of Health (NIH)CompletedNoise-induced Hearing LossUnited States
-
London School of Hygiene and Tropical MedicineUniversity of Cambridge; University of LiverpoolCompletedNoise-induced Hearing Loss and TinnitusUnited Kingdom
-
Baskent UniversityNot yet recruitingNoise Induced Hearing Loss | Noise; Adverse Effect
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States